You are here

iptacopan

Novartis eyes accelerated FDA approval for iptacopan across multiple indications

Novartis eyes accelerated FDA approval for iptacopan across multiple indications

Clinical Trials Arena

clinical trials

IgA nephropathy

Flag link:

EHA 2023 – Astrazeneca keeps up its complement defense

EHA 2023 – Astrazeneca keeps up its complement defense

EP Vantage

Flag link:

Novartis’s iptacopan meets primary endpoint in Phase III PNH trial

Novartis’s iptacopan meets primary endpoint in Phase III PNH trial

Clinical Trials Arena

clinical trials

Flag link:

Could This Be Novartis' Next Blockbuster Medicine?

Could This Be Novartis' Next Blockbuster Medicine?

Motley Fool

Flag link:

ASH: Novartis says rare disease med 'stands on its own,' diving deeper into head-to-head win against AstraZeneca

ASH: Novartis says rare disease med 'stands on its own,' diving deeper into head-to-head win against AstraZeneca

Fierce Biotech

Flag link:

Novartis' iptacopan meets PhIII test in fight against rare blood disease

Novartis' iptacopan meets PhIII test in fight against rare blood disease

Endpoints

clinical trials

paroxysmal nocturnal hemoglobinuria

Flag link:

Novartis, eyeing $3B market, beats AstraZeneca blood disorder blockbusters in phase 3

Novartis, eyeing $3B market, beats AstraZeneca blood disorder blockbusters in phase 3

Fierce Biotech

clinical trials

Flag link:

Novartis’ oral drug iptacopan tops injectables in head-to-head PNH trial

Novartis’ oral drug iptacopan tops injectables in head-to-head PNH trial

Pharmaphorum

clinical trials

Flag link:

Novartis’ iptacopan hits the mark in rare kidney disease C3G

Novartis’ iptacopan hits the mark in rare kidney disease C3G

Pharmaforum

Flag link:

EHA21: Novartis trumpets iptacopan as oral alternative to antibodies in PNH

EHA21: Novartis trumpets iptacopan as oral alternative to antibodies in PNH

Pharmaforum

clinical trials

Flag link:

Novartis' Most Advanced Kidney Compound Shows Promise in C3G

Novartis' Most Advanced Kidney Compound Shows Promise in C3G

BioSpace

clinical trials

Flag link: